Cargando…
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
BACKGROUND: Off-label use (OLU) of a drug reflects a perceived unmet medical need, which is common in oncology. Cancer drugs are often highly expensive and their reimbursement is a challenge for many healthcare systems. OLU is frequently regulated by reimbursement restrictions. For evidence-based he...
Autores principales: | Herbrand, Amanda Katherina, Schmitt, Andreas Michael, Briel, Matthias, Diem, Stefan, Ewald, Hannah, Hoogkamer, Anouk, Joerger, Markus, Mc Cord, Kimberly Alba, Novak, Urban, Sricharoenchai, Sirintip, Hemkens, Lars G, Kasenda, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890379/ https://www.ncbi.nlm.nih.gov/pubmed/31803503 http://dx.doi.org/10.1136/esmoopen-2019-000596 |
Ejemplares similares
-
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
por: Herbrand, Amanda Katherina, et al.
Publicado: (2021) -
Resilience Enhancement Online Training for Nurses (REsOluTioN): Protocol for a Pilot Randomized Controlled Trial
por: Srikesavan, Cynthia, et al.
Publicado: (2022) -
Organisation and timeline of measures in French psychiatric establishments during the first wave of the COVID-19 epidemic: EvOlu’Psy study
por: Legrand, Guillaume, et al.
Publicado: (2021) -
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
por: Ladanie, Aviv, et al.
Publicado: (2018) -
Characteristics and survival of patients with cancer with intended off-label use—a cohort study
por: Schmitt, Andreas Michael, et al.
Publicado: (2022)